Get the content you want anytime you want.
REGISTER NOW | SIGN IN
The Best Infectious Disease News Delivered Weekly

The Contagion® Blood-borne specialty page provides blood-borne-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

BLOOD-BORNE DISEASES NEWS - Page 9

Sofosbuvir-Based Treatment Offers High SVR Rates in Hard-to-Treat HCV Genotype 3 Patients
A new study finds that sofosbuvir-based treatment in a real-life setting offered SVR rates greater than 90% in hard-to-treat HCV genotype 3 patients with advanced liver disease.
Ebola RNA Can Persist in Semen Two Years After Acute Infection Period
A recent study suggests that Ebola virus RNA can remain in the genital tract for more than 2 years following the acute infection period.
Age is No Longer a Barrier to Hepatitis C Treatment with Newer DAAs
A recent study finds that the use of sofosbuvir-based direct-acting antivirals for HCV treatment was effective and well-tolerated in elderly patients.
Hepatitis B Vaccine Continues to Jump Hurdles on Its Way to Potential FDA Approval
The decision date for a NDA for a new hepatitis B vaccine, Dynavax’s Heplisav-B, has been delayed, as the FDA asked for more post-marketing study information on the vaccine.
Risk for Cancer-Causing Infections Highest in Low- and Middle-Income Countries
Despite the progress that has been made, more research is needed on cancer prevention, hepatitis B, and human papillomavirus vaccines.
Treatment as Prevention: A Comprehensive Approach to Hepatitis C Virus in Persons Who Inject Drugs
With IV drug use accounting for 60% of new infections, treatment for individuals in this population is necessary to stave off new infections.
Top 5 <i>Contagion</i>® News Articles for the Week of July 30, 2017
New HIV drugs, vaccine regulations in France, correlations between intestinal viruses & type 1 diabetes, the susceptibility of Florida mosquitoes to transmit chikungunya, and an evaluation of the risk of hepatitis B reactivation in veterans on direct-acting antiviral therapy make up our Top 5 articles for the week of July 30, 2017.
Mavyret Approved for Patients with Chronic HCV Genotypes 1-6 Without Cirrhosis
The US Food and Drug Administration approved Mavyret for adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis or with mild cirrhosis.
FEATURED
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.